The clinical validation of a dried blood spot method for immunosuppressive drugs and creatinine
Recruiting
- Conditions
- Transplant recipients
- Registration Number
- NL-OMON23332
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
Aged 18 and over
-Able to understand written information and able to give informed consent
-Treated with tacrolimus, everolimus, sirolimus and/or ciclosporin
-Able and willing to undergo a finger prick for dried blood spot sampling
-Able and willing to fill in a questionnaire
Exclusion Criteria
-Unable to draw blood samples for study purposes
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Optimizing the correction factor needed and clinically validating a DBS method for tacrolimus, everolimus, sirolimus, ciclosporin and creatinine.
- Secondary Outcome Measures
Name Time Method -Analyzing the differences in the measured concentrations in the dried blood spot made with blood obtained from venous sampling and capillary sampling.<br>-Evaluating the need of a correction factor when measuring the hematocrit in the DBS samples<br>-Analyzing the difference between the drug concentration in the microtainer and filtrate card, to investigate the influence of the filtrate card on the drug concentration